| Secondary |
| Product Used For Unknown Indication |
40.5% |
| Analgesic Therapy |
10.8% |
| Drug Use For Unknown Indication |
8.1% |
| Pain |
8.1% |
| Convulsion |
5.4% |
| Hypertension |
5.4% |
| Hypotension |
5.4% |
| Migraine |
5.4% |
| Migraine Without Aura |
5.4% |
| Neuropathy Peripheral |
5.4% |
|
| Drug Interaction |
22.2% |
| Visual Disturbance |
22.2% |
| Loss Of Consciousness |
11.1% |
| Pharmaceutical Product Complaint |
11.1% |
| Post Procedural Haemorrhage |
11.1% |
| Tubulointerstitial Nephritis |
11.1% |
| Weight Increased |
11.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.7% |
| Drug Use For Unknown Indication |
16.2% |
| Hypertension |
4.5% |
| Depression |
4.4% |
| Blood Cholesterol Increased |
2.9% |
| Supplementation Therapy |
2.8% |
| Diffuse Large B-cell Lymphoma |
2.5% |
| Osteoporosis |
2.2% |
| Prophylaxis |
2.2% |
| Pain |
2.1% |
| Cardiovascular Disorder |
2.0% |
| Rheumatoid Arthritis |
2.0% |
| Dementia |
1.8% |
| Vitamin Supplementation |
1.8% |
| Amnesia |
1.4% |
| Dementia Alzheimer's Type |
1.4% |
| Non-small Cell Lung Cancer |
1.4% |
| Atrial Fibrillation |
1.3% |
| Hepatitis C |
1.3% |
| Bone Disorder |
1.1% |
|
| Weight Increased |
11.6% |
| Flushing |
9.3% |
| Tooth Discolouration |
8.1% |
| Vomiting |
7.0% |
| Weight Decreased |
7.0% |
| Hepatic Enzyme Increased |
5.8% |
| Somnolence |
5.8% |
| Haemorrhage Subcutaneous |
4.7% |
| Nausea |
4.7% |
| Pulmonary Infarction |
4.7% |
| Blood Pressure Inadequately Controlled |
3.5% |
| Dysgeusia |
3.5% |
| Pain |
3.5% |
| Pain In Extremity |
3.5% |
| Paraesthesia |
3.5% |
| Pneumocystis Jiroveci Pneumonia |
3.5% |
| Visual Acuity Reduced |
3.5% |
| Asthenia |
2.3% |
| Bronchitis |
2.3% |
| Chest Pain |
2.3% |
|
| Interacting |
| Chemotherapy |
33.3% |
| Duodenal Ulcer |
33.3% |
| Phytotherapy |
33.3% |
|
|
